---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244683"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:01:04.773592+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q2 net income $1.5M; AT-527 lung data positive, Phase 3 data due 2H21

## Summary
- Net income $1.5M vs net loss $10.0M YoY; collaboration revenue $60.4M from Roche.
- Cash $816.5M at June 30; $50M Roche milestone payment received in July 2021.
- AT-527 active metabolite achieved target antiviral levels in lung lining fluid in healthy volunteers.
- Phase 2 interim showed 0.7 log10 greater viral load reduction vs placebo at Day 2.
- Phase 3 MORNINGSKY and Phase 2 MOONSONG top-line results expected in 2H 2021.

## SEC filing metadata
- accession: 0001193125-21-244683
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/0001193125-21-244683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/d360425d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244683
- JSON: https://secwatch.observer/filing/0001193125-21-244683.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.